How to Reduce Suicidal Thoughts and Impulsivity in Depression
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · May 30, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment method called transcranial Direct Current Stimulation (tDCS) to see if it can help reduce severe suicidal thoughts in people experiencing major depression. The trial will compare the effects of tDCS applied to two specific areas of the brain, the left Dorsolateral Prefrontal Cortex (DLPFC) and the right Orbitofrontal Cortex (OFC), along with standard treatment that patients are already receiving.
To participate, individuals must be at least 18 years old, right-handed, and currently diagnosed with major depressive disorder. They should also have a certain level of depressive symptoms and suicidal thoughts, as measured by specific scales. Participants will be required to give their consent and be part of the French social security system. The study is currently looking for volunteers, and those who join can expect to receive the tDCS treatment alongside their usual care while contributing to important research aimed at improving mental health treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Man or woman older than 18 years oldRight-handed
- • Signed Informed Consent form
- • Subject affiliated to or beneficiary from a French social security regime
- • Inpatient or outpatient at the Adult Psychiatry Service
- • Diagnosis of Major Depressive Disorder according to the 5th edition of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and confirmation by the MINI Structured Clinical Interview
- • MADRS score ≥ 18
- • Beck Scale for Suicide Ideation (BSS) score ≥8
- • Under antidepressant treatment
- • Absence of severe progressive neurologic and/or somatic pathologies (specially tumors, degenerative diseases)
- Exclusion Criteria:
- • tDCS contraindication
- • Younger than 18 years old
- • Left-handed
- • under mood stabilizer and/or antiepileptic
- • treated by ECT or rTMS or tDCS for the current eposide
- • Subject under measure of protection or guardianship of justice
- • Presence of other psychiatric pahtologies
- • Subject beneficiary from a legal protection regime
- • Subject unlikely to cooperate or low cooperation stated by investigator
- • Subject not covered by social security
- • Pregnant woman
- • Subject being in the exclusion period of another study or provided for by the "National Volunteer File"
About Centre Hospitalier Universitaire De Besancon
The Centre Hospitalier Universitaire de Besançon (CHU de Besançon) is a leading academic medical center located in Besançon, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Besançon focuses on a wide range of medical disciplines, fostering collaboration between healthcare professionals and researchers to develop new therapeutic strategies and improve patient outcomes. With a commitment to rigorous scientific standards and ethical practices, the institution plays a vital role in translating research findings into practical applications, ultimately enhancing the quality of care provided to the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, , France
Montpellier, , France
Besançon, , France
Créteil, , France
Patients applied
Trial Officials
Djamila BENNABI, MD PhD
Principal Investigator
CHU de Besançon
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported